| 35.94 1.2 (3.45%) | 04-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 44.83 | 1-year : | 47.82 |
| Resists | First : | 38.38 | Second : | 40.95 |
| Pivot price | 36.88  |
|||
| Supports | First : | 34.24 | Second : | 28.48 |
| MAs | MA(5) : | 35.14 |
MA(20) : | 37.51 |
| MA(100) : | 33.9 |
MA(250) : | 27.26 |
|
| MACD | MACD : | -0.8 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 14.9 |
D(3) : | 9.5 |
| RSI | RSI(14): 44.1 |
|||
| 52-week | High : | 40.95 | Low : | 20.82 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ COLL ] has closed above bottom band by 37.8%. Bollinger Bands are 90.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 36.54 - 36.72 | 36.72 - 36.87 |
| Low: | 34.51 - 34.71 | 34.71 - 34.88 |
| Close: | 35.64 - 35.95 | 35.95 - 36.22 |
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Wed, 17 Apr 2024
Is Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) ROE Of 25% Impressive? - Yahoo Finance
Thu, 11 Apr 2024
Critical Insights From Collegium Pharmaceutical Analyst Ratings: What You Need To Know - Markets Insider
Thu, 11 Apr 2024
Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026 - Yahoo Finance
Tue, 09 Apr 2024
Collegium Pharmaceutical (COLL) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance
Mon, 18 Mar 2024
Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now? - Yahoo Finance
Wed, 13 Mar 2024
3 Reasons Why Collegium Pharmaceutical (COLL) Is a Great Growth Stock - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 33 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 1.4 (%) |
| Held by Institutions | 122.8 (%) |
| Shares Short | 7,120 (K) |
| Shares Short P.Month | 6,720 (K) |
| EPS | 1.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.13 |
| Profit Margin | 8.5 % |
| Operating Margin | 41.1 % |
| Return on Assets (ttm) | 10.2 % |
| Return on Equity (ttm) | 24.6 % |
| Qtrly Rev. Growth | 15.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 17.32 |
| EBITDA (p.s.) | 10.38 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 275 (M) |
| Levered Free Cash Flow | 274 (M) |
| PE Ratio | 27.86 |
| PEG Ratio | 21.4 |
| Price to Book value | 5.86 |
| Price to Sales | 2.07 |
| Price to Cash Flow | 4.27 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|